Should I buy or sell Nxera Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nxera Pharma in the last year. There are currently 2 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "sell" SOLTF shares. View SOLTF analyst ratings or view top-rated stocks .

How have SOLTF shares performed in 2024?

Nxera Pharma's stock was trading at $10.00 on January 1st, 2024. Since then, SOLTF stock has decreased by 2.8% and is now trading at $9.72. View the best growth stocks for 2024 here .

How do I buy shares of Nxera Pharma?

Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:SOLTF

Nxera Pharma (SOLTF) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free SOLTF Stock Alerts

$9.72

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $9.72
▼
$9.72
50-Day Range: $8.65
▼
$13.43
52-Week Range: $8.56
▼
$22.78

Volume: N/A
Average Volume: 2,905 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get Nxera Pharma alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Nxera Pharma Stock (OTCMKTS:SOLTF)

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

SOLTF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SOLTF Stock News Headlines

April 17, 2024 | finance.yahoo.com

Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan

April 15, 2024 | msn.com

Nxera and Handok partner for PIVLAZ supply in South Korea

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 15, 2024 | nasdaq.com

Nxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South Korea

April 15, 2024 | finance.yahoo.com

Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea

April 10, 2024 | americanbankingnews.com

Nxera Pharma (OTCMKTS:SOLTF) Stock Crosses Above 50 Day Moving Average of $9.99

April 8, 2024 | finance.yahoo.com

Nxera Pharma joins the World Orphan Drug Alliance

April 3, 2024 | finance.yahoo.com

Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 31, 2024 | globenewswire.com

Nxera Pharma is the New Name for Sosei Group

March 27, 2024 | finance.yahoo.com

Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma

March 20, 2024 | finance.yahoo.com

Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease

March 11, 2024 | finance.yahoo.com

Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

March 6, 2024 | finance.yahoo.com

Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

March 1, 2024 | finance.yahoo.com

Sosei Group Corporation (SOLTF)

February 15, 2024 | globenewswire.com

Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office

February 13, 2024 | finance.yahoo.com

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

January 22, 2024 | finance.yahoo.com

Sosei Heptares Webinar Presentation for FY2023 Financial Results

January 5, 2024 | finance.yahoo.com

Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer

December 21, 2023 | finance.yahoo.com

Sosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare Conference

December 7, 2023 | finance.yahoo.com

Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

December 6, 2023 | finance.yahoo.com

Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

November 24, 2023 | finance.yahoo.com

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

November 14, 2023 | morningstar.com

Sosei Group Corp 4565

November 10, 2023 | msn.com

Sosei Group reports Q3 results

November 10, 2023 | finance.yahoo.com

Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases

November 10, 2023 | finance.yahoo.com

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

See More Headlines

Receive SOLTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nxera Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:SOLTF
CUSIP: N/A
CIK: N/A
Web: www.sosei.com
Phone: (135) 210-3290
Fax: N/A
Employees: 350
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Shinichi Tamura (Age 75)
Founder & Chairman of the Board
Comp: $1.54M
Mr. Christopher Cargill (Age 40)
Representative Executive Officer, President, CEO & Director
Comp: $1.32M
Mr. Hironoshin Nomura (Age 41)
Executive Officer, Executive VP & CFO
Mr. Toshihiro Maeda
Chief Operating Officer
Mr. Kieran Johnson F.C.A. (Age 55)
Executive Officer, Executive VP & Chief Accounting Officer
Dr. Miles Congreve
Chief Scientific Officer
Mr. Kazuhiko Yoshizumi (Age 70)
Executive Officer, Executive VP & Chief Compliance Officer
Shinichiro Nishishita
VP of Investor Relations & Head of Regulatory Disclosures
Stacey Southall
Associate Director & Head of Biophysics
Ms. Candelle Chong (Age 35)
Executive Officer, Executive VP & Chief of Staff

Key Competitors

View All Competitors

SOLTF Stock Analysis - Frequently Asked Questions

Should I buy or sell Nxera Pharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nxera Pharma in the last year. There are currently 2 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "sell" SOLTF shares.
View SOLTF analyst ratings or view top-rated stocks.
How have SOLTF shares performed in 2024?: Nxera Pharma's stock was trading at $10.00 on January 1st, 2024. Since then, SOLTF stock has decreased by 2.8% and is now trading at $9.72.
View the best growth stocks for 2024 here.
How do I buy shares of Nxera Pharma?: Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SOLTF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nxera Pharma (SOLTF) Stock Price, News & Analysis

About Nxera Pharma Stock (OTCMKTS:SOLTF)

SOLTF Stock Price History

SOLTF Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

SOLTF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info